Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?Lisa Lowry, Kirit M Ardeshna
Leukemia & Lymphoma|July 9, 2008
Case 38: central nervous system lymphoma in a patient previously treated for Wegener's granulomatosisLisa Lowry, Thomas Cairns, Maria Thom, et al.
Journal of Geriatric Oncology|September 28, 2013
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapyLisa Lowry, Paul Smith, David Cunningham, et al.
British Journal of Haematology|April 2, 2014
Age disparities in survival from lymphoma and myeloma: a comparison between US and EnglandDianne Pulte, Maria T Redaniel, Lisa Lowry, et al.
British Journal of Haematology|March 21, 2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCLSally Moore, Irfan Kayani, Karl Peggs, et al.
British Journal of Haematology|November 25, 2010
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%Sajir G Mohamedbhai, Keith Sibson, Teresa Marafioti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2011
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trialLisa Lowry, Paul Smith, Wendi Qian, et al.
Hematological Oncology|April 13, 2017
Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?Muhammad Bilal Abid, Rachel Peck, Muhammad Abbas Abid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Pageof 2